Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Alterity Therapeutics ( (AU:ATH) ).
Alterity Therapeutics Limited has announced that Geoffrey Kempler has ceased to be a director as of November 21, 2025. The announcement details Kempler’s interests in securities, which include fully paid ordinary shares and unlisted options. This change in directorship may influence the company’s strategic direction and investor confidence, given Kempler’s significant holdings and involvement in the company.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapeutic solutions for neurodegenerative diseases. The company is known for its innovative approaches in targeting conditions such as Alzheimer’s and Parkinson’s diseases.
Average Trading Volume: 14,994,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
See more data about ATH stock on TipRanks’ Stock Analysis page.